Emgality 300 mg: First and only CGRP antagonist antibody proven to treat adult patients with episodic cluster headache1,2
Meet Franka
- 1 TO 4 ATTACKS PER DAY during active periods that last 7 weeks, followed by periods (≥3 months) of remission
- Tends to seek medical care DURING ACTIVE CLUSTER PERIODS
- May have already TRIED OTHER TREATMENT OPTIONS
Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the treatment of episodic cluster headache.
SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
References
- Emgality. Prescribing Information. Lilly USA, LLC.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0085.